-.15/sh and $52.66 revs are the mean estimates. with the PPS tanking today (currently $24.85) despite the European Commission marketing authorization announcement and last week's announcement on Abbott expanding its ADC collaboration with SGEN, it seems the Street knows there will be an earnings miss, or at least is betting on it. Of course off label use of Adcetris helps revs, but is there suspicion that approved use sales is going to fall short? Word must be getting out. I see no other reason for the PPS to be tanking this way unless there is expection of lower than expected revs. Anyone have thoughts on this matter. We'll find out on Nov. 8th. If it goes much lower (say $23-24) prior to Nov. 8th, then even a revenue miss will not cause the stock to drop since the bad news will have already been priced in.
Note the tiny volume. SGEN has gone down on good news every single time since I began following it more than five years ago, apparently at the behest of shorts and other bad actors. It generally recovers and then moves higher within three or four days.